Mega-Randomized Clinical Trials for Blockbuster Drugs�Reply

• Autores: John P. A. Ioannidis
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 309, Nº. 16, 2013, págs. 1682-1683
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Mega-trials for blockbusters are readily feasible. There would be no cost for the government or health care system. Drug production cost to industry (as opposed to sales cost) is negligible. The proposed mandate could easily stipulate that blockbuster manufacturers donate drugs and placebos for such trials. Total cost to the industry would be approximately 1% of their cumulative sales for the product.